CAR T-Cell kurapwa muKorea
Unoda kunyoresa kuCAR T-Cell kurapwa muKorea?
Bata nesu kuti upedze kupedzisa masevhisi econcierge.
South Korea is paying a lot of attention to CAR T-cell therapy, which is a new kind of immunotherapy that has made a lot of progress. It involves changing the genes of a patient’s own T cells so they can make chimeric antigen receptors (CARs), which can find cancer cells and kill them. South Korea has done a lot of research and development on CAR T cell therapy, with a number of clinical trials and treatment centres devoted to this new method. CAR T cell kurapa has been successful in South Korea because of the country’s healthcare system and technological knowledge. This has given patients with kanzura yeropa hope and paved the way for more personalized cancer treatments in the region.
CAR T-Cell kurapwa muKorea - Kufambira mberi kwazvino
Chikumi 2023: CAR T-cell therapy yave nzira itsva yekurapa gomarara. Yakashandura nzira yatinorwisa nayo marudzi akasiyana egomarara. Mumakore achangopfuura, South Korea yakafambira mberi zvakanyanya munzvimbo ino, izvo zvinoratidza kuti yakazvitsaurira sei kudzidza uye mazano matsva. Ichi chinyorwa chichataura pamusoro pezvimwe zvezvitsva zvitsva mu CAR T-cell kurapwa muKorea. Ichatarisa pane shanduko huru dzakaisa South Korea pamusoro peiyi ndima.
Miedzo yekiriniki uye Kubvumidzwa Kwemitemo: South Korea yakashingairira miyedzo yekiriniki yeCAR T cell therapy, ichigadzira mamiriro ekunze anokurudzira hunyanzvi uye nehanya inotarisana nemurwere. Nyika yanga iri pamberi mukuedza mishonga yekurapa zvirwere zvehematological pamwe nematumbu akasimba, pakati pedzimwe mhando dzegomarara. Zvikuru, miedzo yekiriniki yakaratidza mhedzisiro yakanaka, izvo zvakaita kuti CAR T cell marapiro abvumidzwe nehurumende kune mamwe mashandisiro.
Kuvandudzwa kweNew CAR Constructs: Vatsvagiri nemasayendisiti muSouth Korea vanga vachishanda nesimba kugadzira zvivakwa zveCAR zvinoita kuti kurapwa kwesero reCAR T kushande uye kuve kwakachengeteka. Izvi zvinosanganisira kuvandudza nzira iyo chimeric antigen receptors inogadzirwa kuitira kuti CAR T masero anogona kuwana zviri nani, kusimudzira, uye kugara mumamota. Shanduko idzi dzakatungamira kune mhedzisiro yekurapa iri nani uye mhedzisiro shoma.
Combination Therapies: Vatsvagiri vekuSouth Korea vakatarisawo mukana wekusanganisa CAR T cell therapy nemamwe marudzi ekurapa, senge immune checkpoint inhibitors uye marapiro akanangana. Vatsvagiri vanoda kuvandudza mwero wekupindura uye kutenderedza matambudziko anokonzerwa nemhando dzakasiyana dzemamota uye nekuvanda kwavanoita kubva kune immune system.
Kugadzira uye Kutengesa: South Korea yakaita budiriro huru mukugadzira maitiro ekugadzira CAR T cell marapirwo akasimba uye anogona kukwidziridzwa. Izvi zvave kuita kuti mishonga iyi iiswe pamusika uye kushandiswa nevanhu vakawanda, izvo zviri kuita kuti vanhu vanoida vakwanise kuwana.
South Korea yave mutungamiri pasi rose muCAR T cell therapy. Yakaita izvi nekushandisa hunyanzvi hwayo hwekutsvagisa, ruzivo rwekiriniki, uye hurongwa hwekutonga kuita kufambira mberi kunoshamisa munzvimbo ino. Kuzvipira kwenyika kune hunyanzvi uye kudyidzana kwayo nharaunda yekutsvagisa kwakatungamira mukusikwa kwezvivakwa zveCAR, miyedzo yekiriniki yakabudirira, uye kutengeswa kwemishonga iyi. Zviitiko zvitsva izvi zvine mukana wakawanda wekushandura mabatirwo egomarara nekuvandudza mhedzisiro yevarwere, kwete muSouth Korea chete asi pasi rose. South Korea ingangove nekukanganisa kukuru mune ramangwana reCAR T cell kurapwa sezvo munda unoramba uchichinja.
CAR T-cell therapy, developed by Novartis and marketed under the brand name Kymriah, is currently being provided by the CAR T-cell Therapy Center to patients under the age of 25 who suffer from B-cell acute lymphoblastic leukaemia or diffuse large B-cell lymphoma. In addition, patients who have refractory diffuse large B-cell lymphoma are the focus of clinical trials being conducted for CRCO1, which was developed by a company based in Korea called Curocell. In addition, because Korea is widely recognised as the CAR T-cell Therapy hub in the world, clinical trials for the CAR T-cell therapy developed by Janssen are also currently being conducted for patients who have relapsed or refractory akawanda myeloma.
Vasati vatanga kurapwa, varwere vari kurapwa neCAR T-cell vanodiwa kuti varongedze zvavanoita nemadhipatimendi akati wandei ezvipatara. Kuti zvive zvakanyatsojeka, nhamba huru yenyanzvi muminda ine hukama hwepedyo nechirwere chinotapukira, neurology, cardiology, uye kutarisirwa kwakanyanya kunobatanidzwa mukutarisira kwakazara kunoitika mushure mekurapwa.
Iyo CAR T-cell therapy centre parizvino iri kutora chikamu mu "Research-oriented Hospital R&D Project" neBazi reHutano neWelfare, uye inotarisirwa kuve nzvimbo yekurapa sero inotungamira-yepamusoro masero kurapa uye kurapwa kwakanangana nemurwere. kune vane haematological oncology varwere. Chirongwa ichi chakatangwa nebazi rezvehutano nekugara zvakanaka.
Ndeapi makambani ane chekuita nekugadzira CAR T-Cells muSouth-Korea?
PaNovember 16, 2022, ViroMed, kambani yekuKorea, yakazivisa hurongwa hwekugadzira mushonga weCAR-T. CAR gene optimization tekinoroji, tekinoroji yekugadzira vector, uye tekinoroji yeex vivo yekuchinjisa majini uye kuwanda kwesero zvese zviripo kune bhizinesi rekuvandudza mishonga yeCAR-T. Mushure mekutengesa "VM801," ViroMed's yega CAR-T tekinoroji, kuUS Bluebird Bio ye56.8 bhiriyoni yakahwina muna Zvita 2015, kambani inoronga kugadzira matatu zvigadzirwa zveCAR-T.
Pamusoro pezvo, AbClon iri kugadzira kurapwa kwegomarara reropa kunoenderana nehunyanzvi hwakagadzirwa nechikwata chekutsvagisa chinotungamirwa naProfessor Jung Jun-ho weSeoul National University muna Kukadzi, iyo yakachengeteka kupfuura ikozvino CAR-T mishonga. Tekinoroji yechikwata ichi inozivikanwa kuzvitsaura kubva kumishonga iripo nekudzikisa zvakanyanya cytokine release syndrome (CRS), inokuvadza padivi pemishonga yeCAR-T inogona kukonzera hypotension, fivha, uye kunyange kufa muvarwere.
Pamusoro pazvo, Green Cross Cell, inotsigira Green Cross, iri kuongorora uye kusimbisa vamiriri veCAR-T mishonga yekurapa gomarara rakasimba. Iyo kambani inotarisira kuita tsvakiridzo kuitira kuti itange kuyedza kusati kwave nekiriniki gore rinouya. Kubva pavakadoma Son Ji-woong semukuru weLife Science Business Division muna Kukadzi, LG Chem inonzi yanga ichifunga nezvekushandisa tekinoroji ine chekuita nemishonga yeCAR-T, nekugadzirwa kwemishonga yechirwere cheshuga nemishonga inorwisa cancer. kukosha kwekambani R&D mishoni.
Curocell, yekutanga yekuSouth Korea biotech yakatanga iyo CAR-T cell therapy, iri kuronga kuparura kuyedza kwekiriniki yerinoveli CAR-T cell therapy inonangana zvese zviri zviviri gomarara reropa uye mamota akasimba.
Curocell achangobva kuendesa chikumbiro cheIND chekiriniki yeCAR-T cell therapy muKorea, uye mukuru wekambani Kim Gun-soo akaudza Maeil Business Newspaper kuti Ministry of Food and Drug Protection inotarisirwa kuibvumidza mwedzi uno.
Curocell yakatoumba mubatanidzwa neSamsung Medical Center kuti itange kutongwa kana yangotenderwa, sekureva kwaKim, anotarisira kuwana kurapwa kwegomarara kuvarwere vekuKorea nekukurumidza.
CAR-T is an immunotherapy that is programmed to identify and destroy cancer cells. T cells from a single patient are genetically engineered in a lab to produce cancer-specific chimeric antigen receptors in order to create this treatment. After that, the cancer-fighting cells are re-infused into the patient’s body.
CAR-T cell therapy yakaratidzwa kuva yakabudirira kudarika mamwe marapirwo egomarara aripo iye zvino. Sekureva kwaKim, kunyangwe akakundikana mamwe marapirwo, 82 muzana yeacute leukemia varwere uye 32-36 muzana yevarwere velymphoma vakave vasina kenza nekamwe CAR-T cell infusion.
Nekudaro, mhedzisiro yepamusoro yeCART inogumira pakurapwa kwemasero egomarara reropa uye haigone kudzokororwa kune akasimba mabundu nekuda kweiyo immune checkpoint receptor (PD-1) inowanikwa mumaseru ezvirwere zvegomarara, ayo anotadzisa immune cell kuita.
Iyo immune yekutarisa receptor inoshanda senge bhureki pane immune cell kugona kushanda. Kana immune checkpoint receptors sePD-1 yakanyanyisa, kugona kwemasero ekudzivirira kubvisa cancer maseru kunoderera, zvichiita kuti kubviswa kwebundu kuome.
Curocell's OVIS (Kukunda Immune Suppression) tekinoroji inokunda chirambidzo ichi, ichibvumira CAR-T cell therapy kuti ishandiswe kurapa mapundu akasimba. OVIS tekinoroji yemajini einjiniya inoshandisa genetic modified yemasero ekudzivirira kudzivirira immune cheki receptor RNA (ribonucleic acid). Mutsva weCAR-T cell therapy yakaitwa neiyi tekinoroji yakabudirira kupfuura yazvino kurapwa kweCAR-T mumuenzaniso wemhuka, sekureva kwaKim.
Kunze kweCurocell's therapy, hapana yeCAR-T cell therapies iripo kana mukiriniki miedzo inonangana nekenza yeropa uye mamota akasimba, sekureva kwaCurocell.
Maitiro ekunyorera sei kuCAR T-Cell kurapwa muKorea?
Tumira marepoti ako ekurapwa ku info@cancerfax.com kana WhatsApp kwavari +1-213 789-56-55. Tumira mishumo inotevera kuti uwane maonero uye fungidziro:
1) Pfupiso yezvokurapa
2) Mishumo yeropa yazvino
3) Biopsy
4) Latest PET Scan
5) Bone marrow biopsy (Kana iripo)
6) Chero mimwe mishumo yakakodzera uye scans
Once our team receives your medical reports, we analyze them and send it to hospitals that are performing CAR T-Cell therapy with that type of cancer and marker. We send reports to the concerned specialist and get his opinion. Report analysis is followed by an online video consultation with the specialist. We also get estimate from the hospital on complete treatment. This helps you in planning for the entire treatment duration.
Kana ukangofunga kushanyira kurapwa, tinoronga tsamba yevhiza yekurapa uye mamwe magwaro anodiwa kubva kuchipatara. Isu tinobatsirawo uye nekukutungamira mukunyorera vhiza yekurapa kumumiriri weKorea. Kana vhiza yagadzirira isu tinobatsira uye nekukutungamira mukugadzirira matikiti ekufamba uye endege. Isu tinorongawo hotera yako uye imba yevaenzi, kana ichidikanwa muSouth-Korea. Pakusvika muguta rekurapa mumiriri wedu achakugamuchirai panhandare yendege.
Mumiriri wedu acharonga kugadzwa kwachiremba uye kuzadzisa zvinodiwa zvekunyoresa iwe. Achakubatsirawo nekupinzwa muchipatara uye nerumwe rubatsiro rwenzvimbo nerutsigiro rwunodiwa. Kana kurapwa kwapera isu ticharonga kuti iwe utevere kubvunzana nachiremba anorapa.
Zvipatara zvepamusoro zveCAR T-Cell kurapwa muKorea
Asan medical centre
South Korea's Asan Medical Center yanga iri pamberi mukushandisa matekinoroji matsva kurapa gomarara reropa, nechinangwa chekuvandudza mhedzisiro yevarwere uye hupenyu hwehupenyu. Nzvimbo iyi yakaisa mari mukucheka-kumucheto matekinoroji senge inotevera-chizvarwa kutevedzana (NGS) yechokwadi genetic mepu yemamota, izvo zvinoita kuti zvikwanise kurapa murwere wega wega. Asan Medical Center yakawedzerawo marapirwo matsva, akadai seCAR T cell therapy, inoshandisa immune system yemurwere kurwisa cancer maseru. Zvishandiso izvi zvakashandura kuti gomarara reropa rinowanikwa sei, rinoteverwa, uye rinorapwa, zvichipa varwere tariro itsva uye kuita kuti Asan Medical Center ive mutungamiri mukurwisa cancer yeropa.
Ndeipi mutengo weCAR T-Cell kurapwa muKorea?
Mutengo weCAR T-Cell kurapwa muSouth-Korea unotanga kubva pamadhora mazana mana nemakumi mashanu ezviuru zveUSD uye unogona kusvika pamadhora mazana mashanu emadhora. zvichienderana nerudzi uye kukura kwechirwere uye mutoro wacho pamuviri. Zvakakosha kuyeuka kuti fungidziro iyi ingori fungidziro chete uye kuti mamiriro chaiwo anogona kuchinja. Mhando chaiyo yeCAR-T therapy, kuoma kwemaitiro, mari yechipatara, rubatsiro rwekutsigira, uye kuwedzera kuongororwa kwekuongorora zvose zvinosiyana zvinogona kukanganisa mutengo. Kudzora mitengo ine chekuita neCAR-T cell therapy, zvinokurudzirwa kuti varwere vataure nenyanzvi dzezvehutano uye vatarise mukuvhara inishuwarenzi kana zvirongwa zvekubatsira mari.
Chii chinonzi CAR T-Cell kurapwa?
Chimeric antigen receptor T-cell therapy, inowanzozivikanwa seCAR T-cell therapy, ivhu-inoputsa immunotherapy iyo yakashandura zvachose nzira iyo kenza inorapwa. Inopa varwere vane mamwe magomarara tariro yaimboonekwa seisingarapike kana kuti ine nzira shoma dzekurapa.
Kurapa uku kunosanganisira kushandisa masero emuviri emuviri wemurwere-kunyanya, T masero-uye kuachinja-chinja kuvandudza kugona kwavo kuona nekuparadza maseru egomarara. Kuti aite izvi, masero eT anopihwa chimeric antigen receptor (CAR), iyo inovapa kugona kunanga mamwe mapuroteni, kana maantigen, pamusoro pemasero egomarara.
Masero eT kubva kumurwere anotanga kubviswa, uye anobva agadziriswa genetically kuratidza CAR. Murabhoritari, masero akachinjwa aya anowanzwa kuti abudise huwandu hwakati wandei hwemasero eCAR T, anozodzoserwa muropa remurwere.
Pavanenge vari mukati memuviri, masero eCAR T anowana masero ekenza anoratidza antigen inodiwa, anonamatira paari, uye anokonzera simba rekudzivirira zvirwere. Masero eCAR T akabatiswa anowedzera uye anoita kurwisa kwakanangana nemasero egomarara, achiauraya.
CAR T-Cell kurapwa inoshanda sei?
Kana ichishandiswa kurapa mamwe maronda eropa senge acute lymphoblastic leukemia (ALL) uye chaiwo mafomu e lymphoma, CAR T-cell therapy yakaratidza mhedzisiro. Yakaburitsa mhinduro dzinozivikanwa uye mune vamwe varwere, kunyangwe kuregererwa kwenguva refu.
CAR T-cell therapy, zvisinei, inzira yakaoma uye yakasarudzika yekurapa inogona kuve nenjodzi nemhedzisiro yakaipa. Cytokine release syndrome (CRS), yakapararira immunological reaction iyo inogona kukonzera zviratidzo-sefuruwenza uye, mumamiriro ezvinhu akaipisisa, kutadza kwenhengo, kunogona kuitika kune vamwe vanhu. Pakave zvakare nemishumo yezvinokonzeresa neurological yakashata, zvisinei iyo inowanzorapika.
Despite these difficulties, CAR T-cell therapy is a significant advancement in the fight against cancer and shows great potential for the future. Current studies are focused on enhancing its efficacy and safety profile as well as extending its uses to different cancer types. CAR T-cell kurapa has the ability to change the face of cancer treatment and give patients everywhere new hope with further advancements.
nzira
Iyo CAR-T kurapwa maitiro, iyo inotora mavhiki mashoma, inosanganisira akawanda matanho:
T masero anotorwa muropa rako uchishandisa chubhu inoiswa mutsinga yeruoko. Izvi zvinotora maawa mashoma.
Masero eT anotakurwa kuenda kunzvimbo uko anogadziridzwa genetic modified kuti ave masero eCAR-T. Vhiki mbiri kana nhatu dzinopfuura mukati meizvi.
Masero eCAR-T anopinzwazve muropa rako kuburikidza nedrip. Izvi zvinoda maawa akawanda.
Masero eCAR-T anotarisa uye anobvisa masero egomarara mumuviri wese. Mushure mekugamuchira CAR-T kurapwa, iwe unozotariswa zvakanyanya.
Imhando ipi yemaseru egomarara anogona kurapwa neCAR-T Cell Therapy?
Varwere chete vane B-cell vasiri lymphoma Hodgkin's kana vana acute lymphoblastic leukemia vakatoedza marapiro maviri asina kubudirira vanogona kushandisa ikozvino CAR T-cell therapy zvigadzirwa zvakagamuchira FDA mvumo. Nekudaro, CAR T-cell therapy yave kuedzwa muzvidzidzo zvekiriniki seyekutanga kana yechipiri-mutsara kurapwa kwevakuru lymphoma uye yevana acute lymphoblastic leukemia. Munguva pfupi yadarika, zvimwe zvezvidzidzo zvakaratidza budiriro inoshamisa muzviitiko zvemamota akasimba senge glioblastoma, gliomas, kenza yechiropa, kenza yemapapu, kenza yeGI, kenza yepancreatic uye. nomumukanwa kenza.
Kupedza
Izvi zvinomiririra kufambira mberi kwakakosha mukutarisira kweleukemia uye B-cell lymphoma. Uyezve, inopa tariro kune avo vaimbofanotaurwa kuti vaizogara mwedzi mitanhatu chete. Zvino zvataona nzira dzekuramba uye nekugadzira mamwe matekiniki ekuzvirwisa, ramangwana rinoita serinonyanya kuvimbisa.
Bata nevatapi vedu vane ruzivo rwakanyanya pano pa CancerFax kubvunzurudzwa kwemahara kugadzira chirongwa chekuchengetedza chakakodzera chezvinodiwa zvehutano hwako. Ndokumbira utumire marepoti ako ekurapa ku info@cancerfax.com kana WhatsApp kune + 1 213 789 56 55.
Ndezvipi zvakanakira zveCAR-T Cell Therapy?
Chakanyanya kubatsira ndechekuti CAR T-cell therapy inongoda kuisirwa kamwe chete uye kazhinji inongoda mavhiki maviri ekuchengetwa kwevarwere. Varwere vane isiri-Hodgkin lymphoma uye leukemia yevana vachangobva kuongororwa, kune rumwe rutivi, vanowanzoda chemotherapy kweinenge mwedzi mitanhatu kana kupfuura.
Zvakanakira zveCAR T-cell therapy, inova iri mushonga mhenyu, inogona kuramba iripo kwemakore mazhinji. Kana uye kana kudzokazve kukaitika, maseru anozokwanisa kuona uye kunanga maseru egomarara nekuti anogona kurarama mumuviri kwenguva yakareba.
Kunyange zvazvo ruzivo ruchiri kusimukira, 42% yevarwere vakuru ve lymphoma vakawana CD19 CAR T-cell kurapwa vakanga vachiri mukuregererwa mushure memwedzi gumi nemishanu. Uye mushure memwedzi mitanhatu, zvikamu zviviri muzvitatu zvevarwere vane acute lymphoblastic leukemia vakanga vachiri mukuregererwa. Nehurombo, varwere ava vaive nemamota ane hasha asina kurapwa nenzira yechinyakare yekuchengeta.
Ndeupi rudzi rwevarwere vangave vagamuchire vakanaka veCAR-T Cell Therapy?
Varwere vari pakati peMakore matatu kusvika kuMakore makumi manomwe vakaedzwa neCAR T-Cell kurapwa kwemhando dzakasiyana dzegomarara reropa uye zvakaonekwa kuti zvinoshanda zvakanyanya. Nzvimbo zhinji dzakati budiriro inopfuura 3%. Munhu anonyatsokwanisa kumirira CAR T-cell therapy panguva ino mwana ane acute lymphoblastic leukemia kana munhu mukuru ane B-cell lymphoma yakakomba anga atova nemitsetse miviri yekurapa kusingashandi.
Gore ra2017 risati rapera, pakanga pasina mwero wakagamuchirwa wekutarisira varwere vanga vatopfuura nemitsetse miviri yekurapa vasina kuwana kuregererwa. Mushonga chete wakatenderwa neFDA kusvika parizvino waratidza kubatsira zvakanyanya kuvarwere ava ndeyeCAR T-cell therapy.
CAR-T Cell therapy inoshanda zvakadii?
CAR T-cell therapy yave ichishanda zvikuru mukurapa mamwe marudzi egomarara reropa, seacute lymphoblastic leukemia (ALL) uye asiri Hodgkin lymphoma. Mumakiriniki ekuedzwa, mazinga ekupindura ave akanaka kwazvo, uye varwere vazhinji vakapinda mukuregererwa kwakakwana. Mune zvimwe zviitiko, vanhu vakanga vaedza mimwe mishonga yose vaiva nekuregererwa kwenguva refu kana kuti kurapa kunobvira.
Chimwe chezvinhu zvakanakisa nezveCAR T-sero kurapwa ndechekuti inonangana nemasero akakodzera. Iwo maCAR receptors akawedzerwa kumasero eT anogona kuwana chaiwo mamaki pamasero egomarara. Izvi zvinoita kuti zvikwanise kupa kurapa kwakanangwa. Iyi nzira yakanangwa inokuvadza maseru ane hutano zvishoma sezvinobvira uye inodzikisa njodzi yemhedzisiro inouya nemishonga yechinyakare senge chemotherapy.
Asi zvakakosha kuyeuka kuti CAR T-cell therapy ichiri nzvimbo itsva ichiri kuchinja. Vatsvagiri uye vanachiremba vari kushanda nesimba kuti vagadzirise matambudziko akaita semutengo wakakwira, mukana wemhedzisiro yakakomba, uye chokwadi chekuti inongoshanda kune mamwe marudzi egomarara.
Pakupedzisira, CAR T-cell therapy yakaratidza kuva nzira yakabudirira zvikuru yekurapa mamwe marudzi egomarara reropa. Kunyangwe iri nzira inovimbisa uye ine simba, kudzidza kwakawanda uye miedzo yekiriniki inodiwa kuivandudza nekutsvaga nzira nyowani dzekuishandisa. CAR T-cell therapy inogona kushandura marapirwo egomarara uye kuita kuti zvinhu zvirinani kuvanhu pasi rose kana ikaramba ichipora.
Inclusion & exclusion criteria
Kusanganisa maitiro eCAR T-cell therapy:
1. Varwere vane CD19+ B-cell Lymphoma (Anenge maviri asati asangana chemotherapy regimens)
2. Kuva ane makore matatu kusvika makumi manomwe nemashanu ekuberekwa
3. ECOG zvibodzwa ≤2
4. Vakadzi vane mikana yekuzvara vana vanofanira kuongororwa weti kuti vane pamuviri uye voonekwa kuti havana kubatwa here vasati varapwa. Vose varwere vanobvumirana kushandisa nzira dzakavimbika dzekudzivirira pamuviri panguva yekuedzwa uye kusvika pakutevera kwenguva yekupedzisira.
Nzira yekusabatanidzwa yeCAR T-cell therapy:
1. Intracranial neBP kana kufenda
2. Kutadza kufema
3. Yakaparadzirwa intravascular coagulation
4. Hematosepsis kana Utachiona husingadzoreki hunoshanda
5. Kusadzora chirwere cheshuga
CAR T-Cell marapiro akatenderwa neUSFDA
B-cell precursor acute lymphoblastic leukemia, yakadzokororwa kana refractory diffuse hombe B-cell lymphoma
Yese mhinduro mwero (CR):> 90%
Chinangwa: CD19
Price: $ 475,000
Nguva yekubvumidza: Nyamavhuvhu 30, 2017
Kudzokororwa kana kudzoreredza kuparadzira hombe B-cell lymphoma, yakadzokororwa kana refractory follicular cell lymphoma.
Non-Hodgkin's lymphoma Yakazara mhinduro mwero (CR): 51%
Chinangwa: CD19
Price: $ 373,000
Nguva yekubvumidza: 2017 Gumiguru 18
Kudzokororwa kana refractory diffuse hombe B-cell lymphoma
Mantle cell lymphoma Yese yekupindura mwero (CR): 67%
Chinangwa: CD19
Price: $ 373,000
Nguva Yakabvumirwa: Gumiguru 18, 2017
Kudzokororwa kana refractory diffuse hombe B-cell lymphoma
Yese yekupindura mwero (CR): 54%
Chinangwa: CD19
Price: $ 410,300
Nguva Yakabvumirwa: Gumiguru 18, 2017
Yakadzokazve kana Refractory Multiple Myeloma
Yese yekupindura mwero: 28%
Chinangwa: CD19
Price: $ 419,500
Yakabvumirwa: Gumiguru 18, 2017
Ndezvipi zvinokonzerwa neCAR-T Cell therapy?
Pazasi pane mamwe emhedzisiro yeCAR T-Cell therapy.
- Cytokine release syndrome (CRS): Iyo yakanyanya kupararira uye ingangove yakakosha mhedzisiro yeCAR T-cell kurapwa ndeye cytokine release syndrome (CRS). Zviratidzo zvakaita sefuruu, zvinosanganisira fivha, kupera simba, kutemwa nemusoro, uye kurwadziwa kwemhasuru, zvinounzwa nekugadziridzwa kweT cell 'kugadzirwa kwemacytokines. Mumamiriro ezvinhu akanyanyisa, CRS inogona kukonzera kupisa kwakanyanya, hypotension, kutadza kwenhengo, uye kunyange mhedzisiro inouraya.
- Neurological Toxicity: Vamwe varwere vanogona kukudziridza mhedzisiro yetsinga, iyo inogona kusimuka mukuomarara kubva kune zvishoma zvakakomba zviratidzo senge kuvhiringidzika kunyoro uye kuvhiringidzika kune zvakakomba zvakanyanya senge pfari, delirium, uye encephalopathy. Mushure meCAR T-cell infusion, neurological toxicity inowanzoitika mukati mevhiki yekutanga.
- Cytopenias: CAR T-sero kurapwa kunogona kukonzera kuderera kwemasero eropa, akadai seanemia (yakaderera masero matsvuku eropa), neutropenia (yakaderera masero eropa eropa), uye thrombocytopenia (yakaderera platelet count). Utachiona, kubuda ropa, uye kupera simba ndedzimwe njodzi dzinogona kuwedzerwa neiyo cytopenias.
- Zvirwere: Iyo CAR T-cell kurapa kudzvanyirira kwemasero ane hutano ekudzivirira muviri kunowedzera njodzi yehutachiona, hutachiona, uye fungal utachiona. Kuti udzivise kutapukirwa, varwere vangangoda kutariswa zvakanyanya uye kupihwa mishonga yekudzivirira.
- Tumor Lysis Syndrome (TLS): Mushure meCAR T-cell therapy, zvinokwanisika mune mamwe mamiriro ezvinhu kuti huwandu hwakawanda hwemukati hubudiswe muropa nekuda kwekukurumidza kuuraya kwebundu maseru. Izvi zvinogona kukonzera kusagadzikana kwemetabolism, senge yakawandisa potassium, uric acid, uye phosphate mazinga, izvo zvinogona kukuvadza itsvo uye kukonzera mamwe matambudziko.
- Hypogammaglobulinemia: CAR T-sero kurapwa ine mukana wekudzikisa antibody synthesis, izvo zvinogona kukonzera hypogammaglobulinemia. Izvi zvinogona kuita kuti utachiona hunoramba huchidzokororwa huwedzere uye zvinodaidzira kuenderera mberi kwemishonga yekutsiva masoja ekudzivirira chirwere.
- Organ toxicity: CAR T-cell therapy ine mukana wekukuvadza nhengo dzakati wandei dzinosanganisira moyo, mapapu, chiropa, neitsvo. Izvi zvinogona kutungamira kune zvisina kujairika renal basa bvunzo, nyaya dzekufema, nyaya dzemoyo, uye kusakwana kwechiropa basa bvunzo.
- Hemophagocytic lymphohistiocytosis (HLH): Chirwere chisingawanzoitiki asi zvichida chinouraya chinouraya chinonzi hemophagocytic lymphohistiocytosis (HLH) chinogona kukura semugumisiro weCAR T-cell therapy. Inosanganisira kuwandisa kwemasero ekudzivirira muviri, izvo zvinokonzera kukanganisa kwakakomba kwenhengo uye kuzvimba.
- Hypotension uye Fluid Retention: Nekuda kweiyo cytokines iyo CAR T masero anoburitsa, vamwe varwere vanogona kukura yakaderera yeropa (hypotension) uye kuchengetwa kwemvura. Kugadzirisa zviratidzo izvi, matanho ekutsigira anosanganisira intravenous fluid uye mishonga inogona kudiwa.
- Secondary Malignancies: Mishumo yezvirwere zvechipiri zviri kubuda zvichitevera CAR T-cell therapy iripo, zvisinei nekushaikwa kwavo. Tsvagiridzo iri kuitwa parizvino pamusoro pekugona kwechipiri hutsinye uye njodzi dzenguva refu.
Zvakakosha kuyeuka kuti havasi murwere wese achava nemigumisiro iyi, uye kuti nhanho yemunhu wega wega inosiyana. Kuti uderedze uye uderedze zvinokonzeresa zvinokonzeresa izvi, timu yekurapa inoongorora varwere nguva isati yasvika, panguva, uye mushure meCAR T-cell therapy.
Time frame
Tarisa pazasi nguva yakazara inodiwa kuti upedze iyo CAR T-Cell kurapwa maitiro. Kunyangwe nguva yakatarwa inotsamira zvakanyanya kureba kwerabhoritari kubva kuchipatara yakagadzira iyo CAR.
- Kuongorora & bvunzo: vhiki imwe
- Pre-kurapwa & T-Cell Kuunganidza: vhiki imwe
- T-Cell kugadzirira & kudzoka: mavhiki maviri-matatu
- 1st Kubudirira kuongororwa: mavhiki matatu
- 2nd Effectiveness analysis: mavhiki matatu.
Yese nguva yakatarwa: 10-12 Mavhiki